These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37155137)

  • 1. Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced Ejection Fraction.
    Mustapic I; Bakovic D; Susilovic-Grabovac Z; Borovac JA
    J Cardiovasc Transl Res; 2023 Oct; 16(5):987-998. PubMed ID: 37155137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
    Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
    Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function.
    Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH
    ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
    Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction.
    Çamcı S; Yılmaz E
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction.
    Alcidi G; Pugliese R; Ioannoni S; Romano M; Palmieri G; Tabella E; Correale M; Di Biase M; Brunetti ND; Iacoviello M
    Clin Pract; 2023 Oct; 13(6):1303-1312. PubMed ID: 37987417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
    Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
    Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction.
    Mustapic I; Bakovic D; Susilovic Grabovac Z; Borovac JA
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614843
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Usman MS; Januzzi JL; Anker SD; Salman A; Parikh PB; Adamo M; Filippatos G; Khan MS; Lala A; Verma S; Metra M; Butler J
    Eur J Heart Fail; 2024 Feb; 26(2):373-382. PubMed ID: 38235936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis.
    Mo X; Lu P; Yang X
    Clin Cardiol; 2023 Oct; 46(10):1137-1145. PubMed ID: 37465885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
    Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
    Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    De Vecchis R; Paccone A; Di Maio M
    Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies.
    Carluccio E; Biagioli P; Reboldi G; Mengoni A; Lauciello R; Zuchi C; D'Addario S; Bardelli G; Ambrosio G
    Cardiovasc Diabetol; 2023 Sep; 22(1):235. PubMed ID: 37660005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
    Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
    BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same.
    Xu L; Pagano JJ; Haykowksy MJ; Ezekowitz JA; Oudit GY; Mikami Y; Howarth A; White JA; Dyck JRB; Anderson T; Paterson DI; Thompson RB;
    J Cardiovasc Magn Reson; 2020 Dec; 22(1):81. PubMed ID: 33267877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.